Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire.

Trial Profile

Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Flibanserin (Primary)
  • Indications Anxiety disorders; Depressive disorders; Premenstrual dysphoric disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Sprout Pharmaceuticals
  • Most Recent Events

    • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
    • 02 Mar 2012 Sprout Pharmaceuticals as company and lead trial centre added as reported by ClinicalTrials.gov.
    • 18 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top